External validation of SCORE2-Diabetes risk prediction model in Chinese patients with diabetes
- 17 April 2025
- journal article
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
Abstract
Aims: The updated 2023 European Guideline recommended SCORE2-Diabetes to estimate cardiovascular disease (CVD) risk in patients with diabetes; however, external validation is lacking. The study aims to validate SCORE2-Diabetes in Chinese and assess its broader applicability and adaptability across diverse settings. Methods and results: This study included patients with diabetes aged 40–90 without prior CVD from a population-based Chinese cohort. Ten-year CVD risk was calculated using the original and recalibrated SCORE2-Diabetes, where four sets of scaling factors for different risk regions were provided. The outcome was defined consistently with SCORE2-Diabetes. During a median follow-up of 7.09 years, 50 426 Chinese patients experienced 6540 CVD events and 2852 non-CVD deaths. The C-statistic of the SCORE2-Diabetes was 0.702 (95% confidence interval: 0.691–0.713) in men and 0.726 (0.716–0.736) in women. The original SCORE2-Diabetes underestimated risk by 30% in men and 50% in women, whereas the recalibrated SCORE2-Diabetes using high-risk region scaling factor had the best calibration, overestimating risk by only 4% in men and underestimating by 7% in women. Of the patients, 14 501 (28.76%) and 20 789(41.23%) were classified as very high (≥20%) and high (10–20%) risk categories, respectively. The significant difference between average baseline and targeted LDL-C was observed in the very high-risk group (2.85 vs. 1.40 mmol/L). Conclusion: With the appropriate selection of the scaling factor, SCORE2-Diabetes shows satisfactory discrimination and calibration in Chinese, indicating its good generalizability. According to the latest guideline, the risk assessment in this real-world population indicated a significant demand for medications with cardiovascular efficacy and a substantial burden for lipid management.Keywords
Funding Information
- Noncommunicable Chronic Diseases - National Science and Technology Major Project of China (2023ZD0503500)
- National Key Research and Development Program of China (2020YFC2003503)
- National Natural Science Foundation of China (82373662)
- Beijing Natural Science Foundation (IS24047)
This publication has 31 references indexed in Scilit:
- Population-Based Recalibration of the Framingham Risk Score and Pooled Cohort EquationsJACC, 2022
- Cardiovascular risk in patients with type 2 diabetes: A systematic review of prediction modelsDiabetes Research and Clinical Practice, 2022
- Cardiovascular risk prediction in type 2 diabetes: a comparison of 22 risk scores in primary care settingsDiabetologia, 2022
- Evaluation of Atherosclerotic Cardiovascular Risk Prediction Models in ChinaJACC: Asia, 2022
- A dynamic risk-based early warning monitoring system for population-based management of cardiovascular diseaseFundamental Research, 2021
- Rationale, design and population description of the CREDENCE study: cardiovascular risk equations for diabetes patients from New Zealand and Chinese electronic health recordsEuropean Journal of Epidemiology, 2021
- Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 DiabetesJAMA Cardiology, 2021
- 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular DiseaseJACC, 2019
- Burden of Cardiovascular Diseases in China, 1990-2016JAMA Cardiology, 2019
- Novel metrics for evaluating improvement in discrimination: net reclassification and integrated discrimination improvement for normal variables and nested modelsStatistics in Medicine, 2011